Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Ligand Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2019 was 91.9%. For fiscal 2018 it was 97.5%, against 96.2% the year before. The highest annual figure on record is 97.5% in fiscal 2018.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 97.5% | +1.3 |
| FY2017 | Dec 31, 2017 | 96.2% | +1.3 |
| FY2016 | Dec 31, 2016 | 94.9% | +3.0 |
| FY2015 | Dec 31, 2015 | 91.9% | +6.1 |
| FY2014 | Dec 31, 2014 | 85.8% | −2.5 |
| FY2013 | Dec 31, 2013 | 88.3% | −0.2 |
| FY2012 | Dec 31, 2012 | 88.5% | +4.9 |
| FY2011 | Dec 31, 2011 | 83.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2019 | Sep 30, 2019 | 87.3% | −9.5 |
| Q2 FY2019 | Jun 30, 2019 | 90.4% | −8.4 |
| Q1 FY2019 | Mar 31, 2019 | 91.1% | −7.5 |
| Q4 FY2018 | Dec 31, 2018 | 95.0% | −2.0 |
| Q3 FY2018 | Sep 30, 2018 | 96.8% | +2.0 |
| Q2 FY2018 | Jun 30, 2018 | 98.7% | −0.3 |
| Q1 FY2018 | Mar 31, 2018 | 98.6% | −0.8 |
| Q4 FY2017 | Dec 31, 2017 | 97.1% | +4.7 |
| Q3 FY2017 | Sep 30, 2017 | 94.8% | – |
| Q2 FY2017 | Jun 30, 2017 | 99.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 99.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 92.4% | – |
See a number that looks wrong?